140 related articles for article (PubMed ID: 25426077)
21. Patients' perspectives regarding long-term warfarin therapy and the potential transition to new oral anticoagulant therapy.
Gebler-Hughes ES; Kemp L; Bond MJ
Ther Adv Drug Saf; 2014 Dec; 5(6):220-8. PubMed ID: 25436104
[TBL] [Abstract][Full Text] [Related]
22. Rivaroxaban in the treatment of venous thromboembolism and the prevention of recurrences: a practical approach.
Arcelus JI; Domènech P; Fernández-Capitan Mdel C; Guijarro R; Jiménez D; Jiménez S; Lozano FS; Monreal M; Nieto JA; Páramo JA
Clin Appl Thromb Hemost; 2015 May; 21(4):297-308. PubMed ID: 25504999
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and safety of apixaban in the patients undergoing the ablation of atrial fibrillation.
Nagao T; Inden Y; Shimano M; Fujita M; Yanagisawa S; Kato H; Ishikawa S; Miyoshi A; Okumura S; Ohguchi S; Yamamoto T; Yoshida N; Hirai M; Murohara T
Pacing Clin Electrophysiol; 2015 Feb; 38(2):155-63. PubMed ID: 25487164
[TBL] [Abstract][Full Text] [Related]
24. Comparison of safety of left atrial catheter ablation procedures for atrial arrhythmias under continuous anticoagulation with apixaban versus phenprocoumon.
Kaess BM; Ammar S; Reents T; Dillier R; Lennerz C; Semmler V; Grebmer C; Bourier F; Buiatti A; Kolb C; Deisenhofer I; Hessling G
Am J Cardiol; 2015 Jan; 115(1):47-51. PubMed ID: 25456870
[TBL] [Abstract][Full Text] [Related]
25. Bilateral lung transplantation in a patient receiving rivaroxaban anticoagulation.
Renner TA; Zalunardo MP; Weder W; Spahn DR
J Cardiothorac Vasc Anesth; 2015; 29(3):723-6. PubMed ID: 25440624
[No Abstract] [Full Text] [Related]
26. Strategies for urgent reversal of target-specific oral anticoagulants.
Davis EM; Uhlmeyer EM; Schmidt DP; Schardt GL
Hosp Pract (1995); 2014 Dec; 42(5):108-25. PubMed ID: 25485923
[TBL] [Abstract][Full Text] [Related]
27. Resolution of left ventricular thrombus secondary to tachycardia-induced heart failure with rivaroxaban.
Nakasuka K; Ito S; Noda T; Hasuo T; Sekimoto S; Ohmori H; Inomata M; Yoshida T; Tamai N; Saeki T; Suzuki S; Murakami Y; Sato K
Case Rep Med; 2014; 2014():814524. PubMed ID: 25477972
[TBL] [Abstract][Full Text] [Related]
28. Tonsillectomy on rivaroxaban.
Saini AT; Schorn VJ; Lin FY
Am J Otolaryngol; 2015; 36(2):280-2. PubMed ID: 25456169
[TBL] [Abstract][Full Text] [Related]
29. Antiplatelet and anticoagulation agents in acute coronary syndromes: what is the current status and what does the future hold?
Huber K; Bates ER; Valgimigli M; Wallentin L; Kristensen SD; Anderson JL; Lopez Sendon JL; Tubaro M; Granger CB; Bode C; Ohman EM; Steg PG
Am Heart J; 2014 Nov; 168(5):611-21. PubMed ID: 25440788
[TBL] [Abstract][Full Text] [Related]
30. Measurement of Non-Vitamin K Antagonist Oral Anticoagulants in Patient Plasma Using Heptest-STAT Coagulation Method.
Du S; Harenberg J; Krämer S; Krämer R; Wehling M; Weiss C
Ther Drug Monit; 2015 Jun; 37(3):375-80. PubMed ID: 25525760
[TBL] [Abstract][Full Text] [Related]
31. Contribution of rivaroxaban to the international normalized ratio when switching to warfarin for anticoagulation as determined by simulation studies.
Siegmund HU; Burghaus R; Kubitza D; Coboeken K
Br J Clin Pharmacol; 2015 Jun; 79(6):959-66. PubMed ID: 25510952
[TBL] [Abstract][Full Text] [Related]
32. Reversal of rivaroxaban-induced alterations on hemostasis by different coagulation factor concentrates – in vitro studies with steady and circulating human blood.
Escolar G; Arellano-Rodrigo E; Lopez-Vilchez I; Molina P; Sanchis J; Reverter JC; Carne X; Cid J; Villalta J; Tassies D; Galan AM; Diaz-Ricart M
Circ J; 2015; 79(2):331-8. PubMed ID: 25482382
[TBL] [Abstract][Full Text] [Related]
33. Managing a Rivaroxaban Bleed: Understanding the Difficulties in Acute Reversal of the New Oral Anticoagulants through a Case Report.
Nannapaneni N; Singh R; Mckay P; Al-Hajeili M
Case Rep Hematol; 2014; 2014():548272. PubMed ID: 25478253
[TBL] [Abstract][Full Text] [Related]
34. Oral anticoagulation in atrial fibrillation.
Ansari JG; Garcha GS; Lakkis N
Cardiovasc Hematol Agents Med Chem; 2014; 12(1):34-41. PubMed ID: 25470152
[TBL] [Abstract][Full Text] [Related]
35. Novel oral anticoagulants in non-valvular atrial fibrillation.
da Silva RM
Cardiovasc Hematol Agents Med Chem; 2014; 12(1):3-8. PubMed ID: 25470147
[TBL] [Abstract][Full Text] [Related]
36. A meta-analysis of phase III randomized controlled trials with novel oral anticoagulants in atrial fibrillation: comparisons between direct thrombin inhibitors vs. factor Xa inhibitors and different dosing regimens.
Providência R; Grove EL; Husted S; Barra S; Boveda S; Morais J
Thromb Res; 2014 Dec; 134(6):1253-64. PubMed ID: 25457584
[TBL] [Abstract][Full Text] [Related]
37. Antithrombotic and anticoagulant therapy for atrial fibrillation.
Dzeshka MS; Lip GY
Cardiol Clin; 2014 Nov; 32(4):585-99. PubMed ID: 25443239
[TBL] [Abstract][Full Text] [Related]
38. Non-vitamin K oral anticoagulants in atrial fibrillation: Where are we now?
Dzeshka MS; Lip GY
Trends Cardiovasc Med; 2015 May; 25(4):315-36. PubMed ID: 25440108
[TBL] [Abstract][Full Text] [Related]
39. Interrupting anticoagulation in patients with nonvalvular atrial fibrillation.
Yates SW
P T; 2014 Dec; 39(12):858-80. PubMed ID: 25516695
[TBL] [Abstract][Full Text] [Related]
40. Randomized, blinded, placebo- and positive-controlled crossover study to determine the effect of multiple doses of apixaban on the QTc interval.
Frost C; Nepal S; Byon W; Moore K; Reeves RA; Boyd R; LaCreta F
J Clin Pharmacol; 2015 May; 55(5):549-55. PubMed ID: 25501868
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
